Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Cascinu S, Berardi R, Bianco R, Bilancia D, Zaniboni A, Ferrari D, Mosconi S, Spallanzani A, Cavanna L, Leo S, Negri F, Beretta GD, Sobrero A, Banzi M, Morabito A, Bittoni A, Marciano R, Ferrara D, Noventa S, Piccirillo MC, Labianca R, Mosconi C, Casadei Gardini A, Gallo C, Perrone F. Cascinu S, et al. Among authors: marciano r. Eur J Cancer. 2021 May;148:422-429. doi: 10.1016/j.ejca.2021.02.023. Epub 2021 Mar 31. Eur J Cancer. 2021. PMID: 33812334 Clinical Trial.
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. Servetto A, et al. Among authors: marciano r. Cancers (Basel). 2021 Sep 30;13(19):4939. doi: 10.3390/cancers13194939. Cancers (Basel). 2021. PMID: 34638422 Free PMC article.
KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer.
Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, Marciano R, Cimminiello C, Bellevicine C, De Placido S, Troncone G. Malapelle U, et al. Among authors: marciano r. Br J Cancer. 2012 Aug 7;107(4):626-31. doi: 10.1038/bjc.2012.275. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805329 Free PMC article.
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R. Di Mauro C, et al. Among authors: marciano r. Br J Cancer. 2017 May 23;116(11):1425-1435. doi: 10.1038/bjc.2017.116. Epub 2017 Apr 25. Br J Cancer. 2017. PMID: 28441382 Free PMC article.
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R. D'Amato C, et al. Among authors: marciano r. Br J Cancer. 2014 Sep 9;111(6):1168-79. doi: 10.1038/bjc.2014.421. Epub 2014 Aug 5. Br J Cancer. 2014. PMID: 25093491 Free PMC article.
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. D'Amato V, et al. Among authors: marciano r. Br J Cancer. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823695 Free PMC article.
69 results